Cargando…

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts

PURPOSE: To investigate the ability of leucovorin (LV) to abrogate dose-limiting toxicities of pralatrexate (PDX) while maintaining efficacy, in vivo. METHODS: H2052 mesothelioma cells were treated with the antifolates methotrexate (MTX), PDX and pemetrexed, with and without LV rescue 24 h later. Ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tedeschi, Philip M., Kathari, Yamini K., Farooqi, Iqra N., Bertino, Joseph R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209237/ https://www.ncbi.nlm.nih.gov/pubmed/25205429 http://dx.doi.org/10.1007/s00280-014-2580-z

Ejemplares similares

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination
por: Tedeschi, Philip M., et al.
Publicado: (2015)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.
por: DeLap, R. J.
Publicado: (1988)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia
por: Oosterom, Natanja, et al.
Publicado: (2019)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Comparative effect of 6S, 6R and 6RS leucovorin on methotrexate rescue and on modulation of 5-fluorouracil.
por: Zittoun, J., et al.
Publicado: (1991)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack
por: Frohman, Elliot M., et al.
Publicado: (2020)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma
por: Noiret, Barbara, et al.
Publicado: (2019)

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
por: Izbicka, E., et al.
Publicado: (2009)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

Phenotypic stability and metastatic behaviour of serially xenografted rat mesotheliomas.
por: Edwards, R. E., et al.
Publicado: (1990)

Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial
por: Bhargava, Mudit, et al.
Publicado: (2023)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment: Erratum
Publicado: (2020)

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
por: Moehler, M, et al.
Publicado: (2005)

Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts
por: Lam, Sze-Kwan, et al.
Publicado: (2017)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers
por: Scotto, Luigi, et al.
Publicado: (2020)

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
por: Kinahan, Cristina, et al.
Publicado: (2020)

Progressive growth of a human pleural mesothelioma xenografted to athymic rats and mice.
por: LindÃ©n, C. J., et al.
Publicado: (1988)

Response of Photofrin-sensitised mesothelioma xenografts to photodynamic therapy with 514 nm light.
por: Foster, T. H., et al.
Publicado: (1996)

Comparative efficacy of 5flourouracil/calcium leucovorine versus 5flourouracil/calcium leucovorine plus oxaliplatin in the adjuvant treatment of colonic carcinoma in Kashmir
por: Shaiq, Hamid Deva, et al.
Publicado: (2013)

Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice.
por: Gibson, S. L., et al.
Publicado: (1994)

Biodistribution and Tumor Uptake of (67)Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
por: Izquierdo-Sánchez, Vanessa, et al.
Publicado: (2018)

Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
por: Offin, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ouk68cph5gbnd78flikm8s3pai